Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place ...

Find out all the key statistics for Biogen Inc. (BIIB), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

BIIB has been the topic of a number of other research reports. Royal Bank of Canada cut their target price on Biogen from $217.00 to $205.00 and set an “outperform” rating on the stock in a ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...